Healthcare Industry News: neuroendocrine tumor
News Release - January 3, 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory BoardNEW YORK--(HSMN NewsFeed)--Delcath Systems, Inc. (NASDAQ: DCTH ) announced today that the Company has appointed three leading, internationally recognized physicians to its newly formed Scientific Advisory Board (“SAB”). The newly appointed members bring expertise in regional cancer therapies, melanoma, neuroendocrine tumors, colorectal cancer and cancers of the limbs. These experts will contribute to the continued development of Delcath Systems’ percutaneous hepatic perfusion (“PHP”) system, a technology designed to isolate and deliver high doses of anti-cancer agents to specific organs or regions of the body, while minimizing the exposure of the drugs to the rest of the body. The System is currently being tested for hepatocellular carcinoma and metastatic liver cancers in Phase II and III clinical trials. The new members include Alexander M.M. Eggermont, MD, PhD, of the Erasmus University Medical Center – Daniel den Hoed Cancer Center in Rotterdam; Douglas L. Fraker, MD, of the University of Pennsylvania Health System; and Larry K. Kvols, MD, of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida.
“Having access to top medical and scientific professionals provides us with the clinical and scientific insights that will focus our development efforts on the areas that hold the most promise for our drug delivery platform,” commented Richard Taney, President and CEO of Delcath Systems. “The establishment of this world class SAB demonstrates Delcath’s commitment to advancing and improving our core technology and to ensuring its clinical and regulatory success. We are excited to work with this group and look forward to adding additional thought leaders to the SAB with expertise in areas of interest to our company in the months ahead.”
About Prof. Alexander M.M. Eggermont, MD, PhD
Professor Eggermont is the Head of the Department of Surgical Oncology at the Erasmus University Medical Center – Daniel den Hoed Cancer Center in Rotterdam, The Netherlands. He holds the Chair of Experimental Surgical Oncology endowed by the Dutch Cancer Society and the “Joseph Maisin Chair” for Surgical Oncology at the Catholique University of Leuven in Belgium.
He specializes in the treatment of melanoma, soft tissue sarcoma, molecular staging methods, and regional cancer treatment techniques such as isolated perfusion of extremities and organs. He is author/coauthor of more than 400 peer reviewed publications, book chapters and monographs. In 1987 he obtained his PhD thesis on “Interferon and IFN-Inducers in the Treatment of Cancer” at the Erasmus University Rotterdam.
About Douglas L. Fraker, MD
Dr. Fraker is Vice Chairman for Clinical Affairs and Chief, Division of Endocrine & Oncologic Surgery in the Department of Surgery at the University of Pennsylvania School of Medicine and Deputy Director, Clinical Services & Programs, at the Abramson Cancer Center of the University of Pennsylvania. Dr. Fraker received his medical degree at Harvard Medical School and came to the University of Pennsylvania School of Medicine in 1995 as the Jonathan E. Rhoads Associate Professor of Surgery.
Prior to joining the Department of Surgery and the Abramson Cancer Center at the University of Pennsylvania School of Medicine, Dr. Fraker was a Senior Investigator and Head of Endocrine Surgery at the National Institutes of Health, Bethesda, Maryland. Dr. Fraker’s research efforts have focused on regional perfusion to treat melanoma and soft tissue sarcomas of the extremities and metastatic tumors of the liver.
About Larry K. Kvols, MD
Dr. Kvols is the Section Head of Neuroendocrine Oncology at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida. Prior to joining the Moffitt Cancer Center in 1999, Dr. Kvols served as the Director and Chief Executive Officer of the Cancer Research & Treatment Center and the Chief of Hematology/Oncology at the University of New Mexico Health Sciences Center in Albuquerque, New Mexico.
With a focus on neuroendocrine and gastrointestinal metastases, Dr. Kvols is the principle investigator on a number of active clinical trials. As a renowned thought leader in his field, Dr. Kvols is a prolific author with nearly 200 authored/coauthored scientific publications and is a frequent guest speaker at neuroendocrine medical conferences. Dr. Kvols is Chairman of the Executive Committee of the North American neuroendocrine tumor Society (NANETS).
About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of 28 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Source: Delcath Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.